San Diego-based Viking Therapeutics marked by itself as a serious competitor within the weight loss drug sector in February after revealing promising facts from the mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented to be a weekly injection and in March the company unveile